Myriad Group AG

MYRN

CH0019624805

Software

Delayed Swiss Exchange Other stock markets			5-day change	1st Jan Change
- ^CHF	-.--%		-27.92%	-62.93%

Jul. 03	Syncona Invests Additional $42.5 Million in Beacon Therapeutics	MT
Jun. 20	Syncona Invests in Two Oncology Companies	MT

Myriad Group AG : New Board Member for Election at the next General Meeting of Shareholders

January 31, 2012 at 12:54 pm EST

MarketScreener.com By

ZURICH, Switzerland - 30 January 2012 - Myriad Group AG (SIX Swiss Exchange: MYRN), the company powering billions of rich mobile social and web experiences on any connected device, today announced that it will propose Erik Hansen as a new non

Latest news about Myriad Group AG

Syncona Invests Additional $42.5 Million in Beacon Therapeutics	Jul. 03	MT
Syncona Invests in Two Oncology Companies	Jun. 20	MT
Syncona Posts Swings to Profit for FY24; Total Investment Income Rises	Jun. 20	MT
Syncona’s Freeline, SwanBio Combine to Form Spur Therapeutics	Jun. 17	MT
Syncona to Sell Stake in Portfolio Company to Century Therapeutics	Apr. 11	MT
Syncona’s Takeover of Freeline Therapeutics Becomes Effective	Feb. 20	MT
Syncona's Fiscal Q3 NAV Declines	Feb. 08	MT
Syncona to Take Over Freeline Therapeutics	Nov. 22	MT
Syncona Swings to Fiscal H1 Loss; Invest Income Falls	Nov. 16	MT
Earnings Flash (SYNC.L) SYNCONA Posts Fiscal H1 Loss GBX-8.01	Nov. 16	MT
Syncona Submits Takeover Bid for Freeline Therapeutics	23-10-18	MT
Syncona Launches Up to GBP40 Million Share Buyback Program	23-09-29	MT
Syncona Flags GBP55 Million Valuation Impact as Novartis' Stops Eye Disease Drug Development	23-09-11	MT
Myriad : Syncona's Gyroscope Therapeutics Says Interim Data Shows GT005 Well Tolerated in Patients With Geographic Atrophy	21-02-12	MT
Myriad : Syncona Expands Investment In Quell Therapeutics By $35 Million	21-02-11	MT
Myriad : Syncona's Expects COVID-19 to Not impact Valuations as Net Asset Value Declines in Q4 2020	21-02-11	MT
Myriad : Syncona's Autolus Prices $100 Million Public Offering in US	21-02-10	MT
Myriad : Syncona Unit Freeline Therapeutics Makes Changes In Clinical Development Plan for Hemophilia B Trial	21-02-08	MT
Myriad : Syncona's Achilles Therapeutics to Continue Clinical Trials on T Cell Therapies to Treat Solid Tumors	21-02-05	MT
Myriad : Syncona's Achilles Therapeutic Mulls IPO in US	21-02-05	MT
Myriad : Syncona Portfolio Company Autolus to Cut 20% Workforce in Q1	21-01-06	MT
Myriad : Syncona Launches New Gene Therapy Company	20-11-19	MT
Myriad : Earnings Flash (SYNC.L) SYNCONA Posts H1 EPS GBX17.86	20-11-19	MT
Myriad Group AG(SWX:MYRN) dropped from Swiss Performance Index (Price Return)	18-04-30	CI
Myriad Group AG Provides Earnings Guidance for the Year Ended December 31, 2017	18-03-20	CI

Chart Myriad Group AG

Duration

Period

More charts

Company Profile

Myriad Group AG is a Switzerland-based company. The Company provides mobile USSD technology, empowering enterprises to deliver new mobile services to enhance customer engagements and improve service delivery, regardless of device or connection. It products and services are integrated within mobile networks, exposing capabilities and core network assets to enterprises, offering unparalleled reach, security, and service.

Sector

Software

More about the company

Sector Other Software

	1st Jan change	Capi.
MYRIAD GROUP AG	-62.93%	0
MICROSOFT CORPORATION	+20.65%	3,371B
SYNOPSYS INC.	+19.25%	94.08B
CADENCE DESIGN SYSTEMS, INC.	+15.90%	86.55B
PALANTIR TECHNOLOGIES INC.	+63.45%	62.51B
DASSAULT SYSTÈMES SE	-22.05%	49.4B
THE TRADE DESK, INC.	+38.19%	48.66B
ATLASSIAN CORPORATION	-23.72%	47.23B
SEA LIMITED	+82.30%	42.4B
TAKE-TWO INTERACTIVE SOFTWARE, INC.	-4.72%	26.84B

Other Software

Myriad Group AG

Equities

MYRN

CH0019624805

Software

Myriad Group AG : New Board Member for Election at the next General Meeting of Shareholders

Latest news about Myriad Group AG

Chart Myriad Group AG

Company Profile

Sector Other Software